newsfilter
← Latest News
GlobeNewswire·

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private placement with